ObesityWeek 2026: Wave outlines case for body composition–based trial design
Across three cohorts in Wave Life Sciences’ mid-stage trial of WVE-007, higher baseline body mass index and excessive body fat have been associated with a more pronounced effect, Rodman & Renshaw said following the company’s ObesityWeek update.
comments(0)
5-min edit window · permanent after that